By the time Enid Katz was two years old, she had already suffered through several bouts of bronchitis and was always hungry, ...

for the treatment of cystic fibrosis in patients with at least one F508del mutation or another treatment-responsive mutation in the CFTR gene. The fixed-dose triple-combination therapy ...

A Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...

Cystic fibrosis is a life-shortening disease with a worldwide prevalence. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in a reduction or absence of CFTR ...

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Ivacaftor oral granules, 25 mg, 50 mg and 75 mg per unit dose packet are indicated for the treatment of cystic fibrosis (CF) in patients aged 4 months and older who have at least one mutation in the ...

Ivacaftor oral granules are indicated for the treatment of cystic fibrosis in patients aged 4 months and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor.

Boucher, University of North Carolina Cystic Fibrosis-Pulmonary Research and Treatment Center. The cystic fibrosis transmembrane regulator (CFTR) gene was isolated as the cause of cystic fibrosis (CF) ...

Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK "This ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

Lupin receives USFDA approval for its generic version of Ivacaftor oral granules, a treatment for cystic fibrosis. The approval marks a significant step for Lupin in the US market.